



Contents lists available at [SciVerse ScienceDirect](http://www.sciencedirect.com)

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc



Corrigendum

Corrigendum to ‘Discovery and pharmacological characterization of *N* [2-({2-[(2*S*)-2-cyanopyrrolidin-1-yl]-2-oxoethyl}amino)-2 methylpropyl]-2-methylpyrazolo[1,5-*a*]pyrimidine-6-carboxamide hydrochloride (anagliptin hydrochloride salt) as a potent and selective DPP-IV inhibitor’ [Bioorg. Med. Chem. 19 (2011) 7221–7227]

Noriyasu Kato^{a,*}, Mitsuru Oka^a, Takayo Murase^a, Masahiro Yoshida^b, Masao Sakairi^a, Satoko Yamashita^a, Yoshika Yasuda^a, Aya Yoshikawa^b, Yuuji Hayashi^a, Mitsuhiro Makino^a, Motohiro Takeda^a, Yakufu Mirensa^c, Takuji Kakigami^b

^a Central Research Laboratory, Sanwa Kagaku Kenkyusho, Co. Ltd, 363 Shiosaki, Hokusei-cho, Inabe-city, Mie 511-0406, Japan

^b Sanwa Kagaku Kenkyusho, Co. Ltd, 35 Higashisotobori-cho, Higashi-ku, Nagoya 461-8631, Japan


^c Xinjiang Medical University, Urumqi 830011, China

The authors regret that Table 1 appeared incorrectly. The corrected table appears below.

^{*} DOI of original article: <http://dx.doi.org/10.1016/j.bmc.2011.09.043>

* Corresponding author. Tel.: +81 594 72 6221; fax: +81 594 82 0072.

E-mail address: n_katoh@mb4.sk-net.com (N. Kato).

Table 1
DPP inhibitory activities of **4**^a

Compound 4	R	IC ₅₀		
		DPP-IV (nM)	DPP-8 (μM)	DPP-9 (μM)
a		3.8	63	60
b		13	76	64
c		32	>100	81
d		1.8	58	45
e		15	>100	66
f		11	43	30
g		80	>100	53
h		28	12	21
i		110	45	28

^a IC₅₀ values are the average of at least two independent experiments.